
N. Nora Bennani, MD, on Diving Deeper Into T-Cell Lymphomas
The assistant professor at Mayo Clinic School of Medicine shared her outlook and predictions on research with T-cell lymphomas.
“T-cell lymphomas, we know, are a heterogeneous group of diseases. But the more we do in terms of genomics, the more we are able to categorize this disease even further into subcategories that have similar responses or non-responses to various therapies. So, if we understand better the various subgroups of T-cell lymphoma, we will know better how to treat them.”
Mayo Clinic is conducting a phase 1 clinical study (NCT03017820) of VSV-IFNβ-NIS, an engineered Vesicular Stomatitis Virus (VSV) therapy, for patients with relapsed/refractory multiple myeloma and T-cell lymphoma (TCL). The trial is currently recruiting. VSV-IFNβ-NIS is a bullet-shaped rhabdovirus which encodes both interferon beta (IFNβ) and sodium iodine symporter (NIS) with particular tumor cell tropism. Viral IFNβ boosts the host's anti-tumor immune response and serves as an indicator of viral proliferation.
The trial’s design was presented at the


























